OBJECTIVE: To estimate the incidence rates for ectopic pregnancy by contraceptive method in a cohort of women using hormonal contraception in Sweden between 2005 and 2016.

METHOD: Women aged 15–49 years with a filled prescription for a hormonal contraceptive in the Swedish Prescribed Drug Register between 2005 and 2016 were included. For each woman, all exposed woman-years were allocated to treatment episodes depending on the method of contraception. Treatment time started on the day the prescription was filled and ended on the first day of the end of supply, new eligible dispensing, pregnancy-related diagnosis and its associated estimated last menstrual period, or removal procedure. Ectopic pregnancy was defined as having at least two records of International Classification of Diseases, Tenth Revision code O00-, including O00.0, O00.1, O00.2, O00.8, O00.9, within 30 days or one episode of O00- and one surgical procedure for ectopic pregnancy (NOMESCO Classification of Surgical Procedures code LBA, LBC, LBD, LBE, LBW). Incidence rates per 1,000 woman-years and 95% CIs were calculated for each method of contraception.

RESULTS: The study included 1,663,242 women and 1,915 events of ectopic pregnancy. The incidence rate (95% CI) for ectopic pregnancy per method of hormonal contraception was estimated: 13.5-mg levonorgestrel (LNG) hormonal intrauterine device (IUD), 2.76 (2.26–3.35) per 1,000 woman-years; 52-mg LNG hormonal IUD, 0.30 (0.28–0.33) per 1,000 woman-years; combined oral contraception, 0.20 (0.19–0.22) per 1,000 woman-years; progestogen implants, 0.31 (0.26–0.37) per 1,000 woman-years; oral medium-dose progestogen (desogestrel 75 mg), 0.24 per 1,000 woman-years; progestogen implants, 0.31 (0.26–0.37) per 1,000 woman-years; oral low-dose progestogen (norethisterone 0.35 mg and lynestrenol 0.5 mg), 0.81 (0.70–0.93) per 1,000 woman-years.

CONCLUSION: Hormonal contraception lowers the risk of ectopic pregnancy markedly. The incidence rate of ectopic pregnancy among women using a low-dose hormonal IUD (13.5 mg LNG) was substantially higher than that in women using other types of hormonal contraception. This study provides real-world evidence to inform best clinical practice for women-centered contraceptive counseling.

Ectopic pregnancy is a major cause of maternal morbidity and mortality globally, accounting for approximately 4% of the maternal mortality in the United Kingdom. Ectopic pregnancy also causes significant morbidity in the form of surgical procedures, medication with methotrexate, and reduced fertility, which may result in subsequent need for assisted reproductive technology. Approximately 2% of all pregnancies are ectopic. In Sweden, where the current study took place,
the average incidence rate of ectopic pregnancy from 2008 to 2016 was approximately 0.83 cases per 1,000 woman-years for ages 15–49 years. The incidence has increased in the past decade, and contraception failure has been discussed as one plausible factor contributing to the increase. In 2019, 49% of all women of reproductive age (15–49 years) worldwide were using some form of contraception.

It is estimated that approximately 450 million women use hormonal or intrauterine contraception daily worldwide. Hormonal contraception may be either a combination of estrogen and a progestogen (pills, patches, or vaginal rings) or progestogen only (pills, intrauterine devices [IUDs], implants, or injections). The most effective protection from experiencing an ectopic pregnancy is to use a modern contraceptive method and, thereby, reduce risk of unintended pregnancy. Long-acting reversible contraception, including hormonal IUDs, are user independent with a low risk of unintended pregnancy and, in Sweden, are often favored by young nulliparous women. However, if pregnancy occurs, approximately 25–50% of these pregnancies are ectopic pregnancies. The risk of ectopic pregnancy with use of other hormonal contraception is less studied. There are studies indicating that progestogen-only hormonal contraception is associated with an increased risk of ectopic pregnancy. Currently, there are three types of hormonal IUDs available on the European market (including Sweden), containing 13.5, 19.5, and 52 mg of levonorgestrel (LNG). The hormonal IUD with 13.5 mg LNG with a smaller insertion tube was introduced in Sweden in 2014. After its introduction, use of hormonal IUDs in nulliparous women increased significantly. The hormonal IUD with the lowest dose has been reported in a small study (N=1,040 women) to be associated with a higher risk of ectopic pregnancy when compared with the 52-mg LNG hormonal IUD. In 2017, new text about the risk of ectopic pregnancy was included in the summary of products characteristics.

The aim of this population-based national register study was to estimate the incidence rate for ectopic pregnancy by contraceptive method in a cohort of women aged 15–49 years using hormonal contraception in Sweden between 2005 and 2016.

METHODS

Sweden has population-based national registers, which include information for all inhabitants on demographic and health indicators such as births, dispensed drugs, and hospital contacts. The population of Sweden is approximately 10 million, and the Swedish government has given consent for each individual’s data to be included. All registers include the civil registration number of each resident, a unique number assigned at birth or immigration that allows linkage of individual data between registers. We obtained linked data from three national registers: the Prescribed Drug Register, the National Patient Register, and the Medical Birth Register. The Medical Birth Register includes maternal data such as parity, the date of the last menstrual period, and pregnancy outcomes including date of birth of the neonate. The Prescribed Drug Register includes data on dispensed substances, dispensed dose, package sizes, and formulations according to the Anatomical Therapeutic Chemical (ATC) Classification System, including the date of dispensation, from July 1, 2005. The National Patient Register includes all in-patient admissions and outpatient visits to the Swedish hospitals, and their associated diagnosis according to the International Classification of Diseases, Tenth Revision (ICD-10) codes.

In a Swedish setting, most women receive contraceptive counseling by midwives at booked appointments or during drop-in visits at maternity health clinics. Most contraceptive counseling and prescription is performed by midwives within the public health system and free of charge. All medication, including hormonal contraception, is free of charge for women aged 18 years or younger. For women up to 26 years of age, contraception is subsidized. Hormonal contraception requires a prescription. Removal of long-acting reversible contraceptives is performed free of charge by a midwife at patient request. Women who choose to have contraceptive counseling, prescription, insertion, or removal performed by a medical doctor pay a fee for the visit.

In Sweden, all suspected cases of ectopic pregnancy are routinely referred by any health care professional to hospital care because of the need for rapid follow-up, repeated serum human chorionic gonadotropin testing, and assessment for surgical or medical (methotrexate) treatment.

All women in Sweden registered in the Prescribed Drug Register with a filled prescription of a hormonal contraceptive (ATC code G02B or G03A), excluding spermicides (ATC code G02BB) and emergency contraceptive pills (ATC code G03AD01 or G03AD02), between July 1, 2005, and December 31, 2016, were included in the study population. Eligible dates were all dates with filled prescriptions of a unique ATC code, excluding dates with filling of two or more different contraceptives. The date of the
first filled eligible prescription during the study period was defined as the index date. Women older than age 50 years and women who had undergone a sterilization procedure before the index date were excluded from the source population. All women were followed from the index date until their 50th birthday, sterilization, death, emigration, or the administrative end of the study data linkage (December 31, 2016).

For each woman, all exposed woman-years were allocated to treatment episodes, depending on the method of contraception: hormonal IUDs containing 13.5 mg (ATC code G02BA) or 52 mg LNG (ATC code G02BA), combined hormonal contraceptives (patches ATC code G03AA13, vaginal rings ATC code G02BB0, and pills ATC codes G03AA and G03AB), etonogestrel implants (ATC code G03AC08), oral medium-dose progestogen-only (desogestrel 75 mg, ATC code G03AC09), oral low-dose progestogen-only (norethisterone 0.35 mg and lynestrenol 0.5 mg, ATC code G03AC01-02), and medroxyprogesterone acetate injections (ATC code G03AC06). Unexposed time was not included.

The length of treatment time started at dispensing date and ended on the first day of end of supply, new eligible dispensing, pregnancy related diagnosis and its associated estimated last menstrual period, or removal procedure (for IUDs or implants). Individual dispensings were summed into treatment episodes by adding the treatment time for each dispensing with a maximum gap of seven days [grace period] between stop of the current dispensing and start of next dispensing of the same contraceptive agent. Women could reenter the cohort with a new dispensing of a prescription.

_Ectopic pregnancy_ was defined as at least two records of ectopic pregnancy (ICD-10 code O00–, including O00.0, O00.1, O00.2, O00.8, O00.9) within 30 days or one record of ectopic pregnancy and a procedure code for surgery for ectopic pregnancy [NOMESCO Classification of Surgical Procedures code LBA, LBC, LBD, LBE, LBW] during the same treatment episode. Within the 30-day window, the first fulfilled definition of ectopic pregnancy was used as the date for the outcome.

The survival curves were adjusted for the identified available confounders age (younger than 40 years, 40 years or older), diagnosis of endometriosis (ICD-10 code N80, yes or no), and previous ectopic pregnancy (defined as above, yes or no).

Baseline characteristics of the study population were expressed as numbers and proportions. The number of events (ectopic pregnancies) and woman-years for each contraceptive method and risk factor were tabulated. Incidence rates by contraceptive method and by risk factor were calculated with 95% confidence limits using Byar’s method. A sensitivity analysis excluding treatment episodes with a history of ectopic pregnancy was performed.

A Cox regression model adjusted for age, history of endometriosis, previous ectopic pregnancy, and contraceptive class was fitted to time to ectopic pregnancy, assuming proportional hazards between levels within each covariate. The analytic unit was treatment episodes, allowing each woman to contribute more than once and to more than one contraceptive method. The fitted model was used for prediction (as opposed to those observed directly in the data) of survival probabilities and was presented as graphs of 1-P compared with survival time in years for each specific combination of age, history of endometriosis, and previous ectopic pregnancy covering the 13.5-mg LNG hormonal IUD and the three most common hormonal contraceptive methods (52-mg LNG hormonal IUD, combined oral contraception, and oral medium-dose progestogen-only contraception). Ethical permission for the study was granted by the regional ethical committee in Stockholm (diary number 2014/1884-31).

**RESULTS**

The study population included a total of 1,663,242 women who contributed a total of 6,807,293 treatment episodes, which totalled 6,960,110 woman-years. Figure 1 describes the study population flow chart. The study participants had a mean age of 27 years, and the majority (64%) were nulliparous at the inclusion in the cohort. Table 1 describes the baseline characteristics of the participants at the index date. Combined oral contraception contributed the most woman-years (40.1%) in the cohort, followed by the 52-mg LNG hormonal IUD (24.7%). Table 2 shows the total prescriptions and associated number of woman-years per contraceptive method.

There were 1,915 ectopic pregnancies during the study period resulting in an incidence rate of 0.28 per 1,000 woman-years (95% CI 0.26–0.29). Among women with a history of endometriosis, the incidence rate was 0.25 (95% CI 0.12–0.44) per 1,000 woman-years and was 6.09 (95% CI 4.88–7.50) per 1,000 woman-years for women with a history of ectopic pregnancies. No woman in the study had both a history of previous ectopic pregnancy and endometriosis at time of inclusion in the cohort.

The 13.5-mg LNG hormonal IUD was used by 2.3% of the study population, of whom 104 had an ectopic pregnancy (incidence rate 2.76 per 1,000
woman-years, 95% CI 2.26–3.35). The hormonal 52-mg LNG IUD was used by 26.1% of the study population, of whom 522 had an ectopic pregnancy (incidence rate 0.30 per 1,000 woman-year, 95% CI 0.28–0.33). Table 2 and Figure 2 describe the incidence rates per method of hormonal contraception in detail. The sensitivity analysis excluding treatment episodes with a history of ectopic pregnancy (0.3%) decreased the incidence rates by 0.01–0.03 (data not shown).

The Cox regression models adjusted for history of ectopic pregnancy and endometriosis and stratified by age group are presented in Appendix 1, available online at http://links.lww.com/AOG/C638, showing the relatively higher predicted risk for ectopic pregnancy in women with a history of ectopic pregnancy independent of method of hormonal contraception. The highest predicted risk for ectopic pregnancy was seen in women younger than age 40 years with a previous history of ectopic pregnancy using the 13.5-mg LNG IUD. According to the model, approximately nine cases of ectopic pregnancy in 100 treatments are expected for the 13.5-mg LNG IUD during 2.5–3 years of use in this specific subset of the study population.

DISCUSSION

In this large, population-based prospective cohort study among women of reproductive age using hormonal contraception, the risk of ectopic pregnancy was highest among the women using 13.5-mg LNG hormonal IUDs (2.76 per 1,000 woman-years) compared with all other methods of hormonal contraception, which had similar highly protective rates. The results support the findings from a hospital-based study in which low-dose hormonal IUDs were associated with lower protective effects compared with higher-dose hormonal IUDs.18

The overall incidence rate of ectopic pregnancy in the study population was low, 0.28 per 1,000 woman-years from 2005 to 2016, as compared with the average approximate incidence rate of 0.83 per 1,000 woman-years for those aged 15–49 years in the Swedish population between 2008 and 2016.6 This suggests that all the hormonal contraceptives effectively prevented pregnancies to varying degrees and subsequently lowered the absolute risk of ectopic pregnancy. The current study supports previous findings that progestogen-only methods may be associated with a lesser protective effect than combined methods.16 This may be explained by the fact that many women continue to ovulate during use of hormonal IUDs and oral low-dose progestogen-only pills.

When adjusting the results for previous ectopic pregnancy or endometriosis, the effect of age is clearly demonstrated, with women younger than age 40 years having a higher predicted relative risk of ectopic pregnancy independent of the use of hormonal contraception. This is expected because of their

Table 1. Baseline Characteristics of Women in the Study Population at the Time of the First Contraceptive Dispensing, July 1, 2005–December 31, 2016 (N=1,663,242)

| Characteristic                  | Value                      |
|---------------------------------|----------------------------|
| Age (y)                         | 27.0±9.9                   |
| Younger than 15                 | 59,368 (3.6)               |
| 15–19                          | 513,146 (30.9)             |
| 20–29                          | 481,773 (29.0)             |
| 30–39                          | 376,020 (22.6)             |
| 40–50                          | 232,935 (14.0)             |
| Highest level of education     |                            |
| Elementary school               | 402,134 (24.2)             |
| High school                     | 544,385 (32.7)             |
| College or university           | 418,262 (25.2)             |
| Postgraduate                    | 5,257 (0.3)                |
| Missing                         | 293,204 (17.6)             |
| Parity                          |                            |
| 0                              | 1,059,003 (63.7)           |
| 1                              | 15,404 (9.3)               |
| 2 or more                      | 448,835 (27.0)             |
| Country of birth                |                            |
| Sweden                          | 1,421,169 (85.5)           |
| Nordic countries except Sweden  | 27,361 (1.7)               |
| EU except the Nordic countries  | 43,223 (2.6)               |
| Europe except EU and Nordic     | 35,340 (2.1)               |
| Asian                           | 86,558 (5.2)               |
| Other                           | 48,962 (2.9)               |
| Missing                         | 629 (0.0)                  |
| Medical history                 |                            |
| Previous ectopic pregnancy     | 36 (0.0)                   |
| Endometriosis                   | 11,675 (0.7)               |

EU, European Union.
Data are mean±SD or n (%).
higher fertility. For all subgroups, the 13.5-mg LNG hormonal IUD was associated with the lowest protective effect, most evident for the women with a history of ectopic pregnancy, which has been reported previously.15

The strength of this study is its large population size, with prospectively collected data comprising all women in Sweden using hormonal contraception during the study period, assuring generalizability of the results and reduced risk of selection or recall bias. The Swedish population-based National Patient Register contains information on all inpatient and outpatient care in the Swedish hospitals, allowing information on known risk factors such as history of ectopic pregnancy or endometriosis to be included. The analyses were adjusted for women with a diagnosis of endometriosis, a common condition, but the prevalence may be underestimated when using diagnosis data from the patient register, because severe cases of endometriosis are predominantly seen in hospitals. Consequently, the effect of endometriosis on ectopic pregnancy may be overestimated. The data were not adjusted for other known risk factors of ectopic pregnancy, including history of pelvic inflammatory disease, chlamydia infection, or tubal surgery, because none of these conditions are contraindications for the use of any of the hormonal contraceptive methods, including IUD.21,22

The limitations of the study include the lack of information on smoking in the Swedish health registers. Smoking is a possible contraindication for combined oral contraception, especially if the woman

Table 2. Number of Treatment Episodes, Ectopic Pregnancies, and Woman-Years Per Hormonal Contraceptive Method, Sweden, 2005–2016

| Type of Hormonal Contraception | No. of Women | No. of Treatment Episodes | Median Follow-up (y) | No. of Ectopic Pregnancies | Woman-Years | Proportion of Total Woman-Years (%) | IR/1,000 Woman-Years | 95% CL |
|-------------------------------|--------------|----------------------------|----------------------|----------------------------|-------------|-------------------------------|----------------------|--------|
| Any contraceptive             | 1,663,242    | 6,807,293                  | 0.5                  | 1,915                      | 6,960,110   | 0.28                          | 0.26–0.29            |
| Hormonal IUD                 |              |                            |                      |                            |             |                               |                      |        |
| 13.5 mg LNG                  | 37,539       | 37,731                     | 0.87                 | 104                        | 37,647      | 0.5                           | 2.76                 | 2.26–3.35 |
| 52 mg LNG                    | 434,242      | 523,391                    | 3.27                 | 522                        | 1,719,652   | 24.7                          | 0.30                 | 0.28–0.33 |
| Combined hormonal contraception |          |                            |                      |                            |             |                               |                      |        |
| Vaginal                      | 154,265      | 405,432                    | 0.29                 | 54                         | 206,875     | 3.0                           | 0.26                 | 0.20–0.34 |
| Patch                        | 40,320       | 77,176                     | 0.34                 | 20                         | 40,979      | 0.6                           | 0.49                 | 0.30–0.75 |
| Oral                         | 973,704      | 2,932,214                  | 0.62                 | 566                        | 2,790,107   | 40.1                          | 0.20                 | 0.19–0.22 |
| Etonogestrel implant         | 188,257      | 251,232                    | 2.16                 | 149                        | 479,066     | 6.9                           | 0.31                 | 0.26–0.37 |
| Progestogen-only contraception |          |                            |                      |                            |             |                               |                      |        |
| Medium-dose (oral, desogestrel 75 mg) | 657,078 | 1,783,618                  | 0.42                 | 286                        | 1,181,276   | 17.0                          | 0.24                 | 0.21–0.27 |
| Low-dose (oral, norethisterone 0.35 mg and lynestrenol 0.5 mg) | 150,597 | 394,696 | 0.46 | 198 | 245,180 | 3.5 | 0.81 | 0.70–0.93 |
| Mestranol acetate injection | 91,800       | 401,803                    | 0.36                 | 16                         | 259,327     | 3.7                           | 0.06                 | 0.04–0.10 |

IR, incidence rate; CL, confidence limit; IUD, intrauterine device; LNG, levonorgestrel.
is older than age 40 years. This may influence the results; however, we judge this effect to be minor. Other limitations include difficulties confirming the actual use of contraception. It is known that early discontinuation rates differ between methods of hormonal contraception.\textsuperscript{23,24} In the current study it is assumed that the women are currently using the prescribed hormonal contraception if they filled a prescription valid for a certain period and have no record in the registers for indicating otherwise (such as a pregnancy related diagnosis, or removal procedure for IUD or implant). Records of filled prescriptions do not capture actual use. We therefore do not know whether or when the dispensed contraception is used but make the assumption that use, and therefore treatment time, begins on the date of dispensation. Hence, the study may underestimate the protective effect of hormonal contraception on the risk of ectopic pregnancy. Further, the Prescribed Drug Register does not include treatment without prescription (eg drugs given during inpatient care). However, because hormonal contraception is exclusively prescribed as outpatient care, the potential missed treatment episodes are assumed to be negligible in this study. The risk of missing cases of ectopic pregnancy is assumed to be small, because all cases of ectopic pregnancy in Sweden are referred to hospitals for assessment of need for surgical or medical treatment and follow-up. The 13.5-mg LNG IUD has been available on the market in Sweden since January 2014. Because our study period ended in 2016, we could not study the effects on the risk of ectopic pregnancy for the 3-year duration of its use in the majority of the users. In a previous study from our research team, the risk of ectopic pregnancy among users of the 13.5-mg LNG hormonal IUD was highest in the beginning of use.\textsuperscript{18} This may indicate a possible overestimation of the risk of ectopic pregnancy among users of the 13.5-mg LNG hormonal IUD in the current study. However, the more than fivefold relative higher incidence rate of ectopic pregnancy for the 13.5-mg LNG hormonal IUD is unlikely to be fully explained by this overestimation.

These findings are clinically relevant for providing real life evidence when providing counseling about methods of contraception to women who wish to preserve fertility. Hormonal IUDs are user-friendly and safe to use, providing women with highly effective and reversible long-acting contraception with few side effects. The results of the current study indicate that the 13.5-mg LNG hormonal IUD should not be recommended for women who are concerned about the risk of ectopic pregnancy. The 13.5-mg LNG hormonal IUD was marketed to a younger (or primiparous) population owing to its smaller size compared with the 52-mg LNG hormonal IUD. A hormonal IUD containing 19.5 mg LNG and with the same size as the 13.5-mg LNG hormonal IUD was approved for the Swedish market in November 2016. Hence, it has not been possible to study the product during the current study period. Further research is needed on the 19.5-mg LNG hormonal IUD and risk of ectopic pregnancy in real-life settings.
REFERENCES

1. Kumar V, Gupta J. Tubal ectopic pregnancy. BMJ Clin Evid 2015;2015:1406.

2. Baggio S, Garzon S, Russo A, Ianniucciolo CQ, Santi L, Laganà AS, et al. Fertility and reproductive outcome after tubal ectopic pregnancy: comparison among methotrexate, surgery and expectant management. Arch Gynecol Obstet 2021;303:259–68. doi: 10.1007/s00404-020-05749-2

3. Varma R, Gupta J. Tubal ectopic pregnancy. BMJ Clin Evid 2012;2012:1406.

4. Li J, Jiang K, Zhao F. Fertility outcome analysis after surgical management of tubal ectopic pregnancy: a retrospective cohort study. BMJ Open 2015;5:e007339. doi: 10.1136/bmjopen-2014-007339

5. Farquhar CM. Ectopic pregnancy. Lancet 2005;366:583–8. doi: 10.1016/S0140-6736(05)67103-6

6. National Board of Health and Welfare. Statistics database for pregnancies, births and newborns from the Swedish Medical Birth Register. Accessed March 24, 2021. https://sdb.socialstyrelsen.se/if_par/resultat.aspx

7. Rana P, Kazmi I, Singh R, Afzal M, Al-Abbasi FA, Aseeri A, et al. Fertility and reproductive outcome after tubal ectopic pregnancies, births and newborns from the Swedish Medical Birth Register. Accessed March 24, 2021. https://sdb.socialstyrelsen.se/if_par/resultat.aspx

8. United Nations Department of Economic and Social Affairs, Population Division. World fertility and family planning 2020: highlights. United Nations; 2020.

9. United Nations Department of Economic and Social Affairs, Population Division. Contraceptive use by method 2019: data booklet. Accessed March 24, 2021. https://www.un.org/development/desa/pd/files/documents/2020/Jan/un_2019_contraceptiveusebymethod_data booklet.pdf

10. Rosenstock JR, Peipert JF, Madden T, Zhao Q, Secura GM. Continuation of reversible contraception in teenagers and young women. Obstet Gynecol 2012;120:1298–303. doi: 10.1097/AOG.0b013e31827499bd

11. Heinemann K, Reed S, Moehner S, Minh TD. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. Contraception 2015;91:280–3. doi: 10.1016/j.contraception.2015.01.011

12. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012;366:1998–2007. doi: 10.1056/NEJMoa1110855

13. Antell K, Deshmukh P, Brown EJ. Contraception update: intrauterine devices. FP Essent 2017;462:20–4.

14. Barnhart KT. Clinical practice. Ectopic pregnancy. N Engl J Med 2009;361:379–87. doi: 10.1056/NEJMcp0810384

15. Li C, Zhao WH, Zha Q, Cao SJ, Ping H, Xi X, et al. Risk factors for ectopic pregnancy: a multi-center case-control study. BMC Pregnancy Childbirth 2015;15:187. doi: 10.1186/s12884-015-0613-1

16. Callahan R, Yacobson I, Halpern V, Nanda K. Ectopic pregnancy with use of progesterin-only injectables and contraceptive implants: a systematic review. Contraception 2015;92:514–22. doi: 10.1016/j.contraception.2015.08.016

17. Parazzini F, Ferraroni M, Tozzi L, Benzi G, Rossi G, La Vecchia C. Past contraceptive method use and risk of ectopic pregnancy. Contraception 1995;52:93–8. doi: 10.1016/0001-6736(95)00142-5

18. Graner S, McTaggart J, Nordström F, Melander E, Widenberg J, Kopp Kallner H. Levonorgestrel intrauterine contraceptive systems (13.5 mg and 52 mg) and risk of ectopic pregnancy. Acta Obstet Gynecol Scand 2019;98:937–43. doi: 10.1111/aogs.13564

19. Ludvigsson JF, Almqvist C, Bonamy AK, Ljung R, Michaelsson K, Neovius M, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol 2016;31:125–36. doi: 10.1007/s10655-016-0117-y

20. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharma-coepidemiol Drug Saf 2007;16:726–35. doi: 10.1002/pds.1294

21. FSRH UK medical eligibility criteria for contraceptive use (UK MEC). Accessed December 1, 2021. https://www.fsrh.org/standards-and-guidance/uk-medical-eligibility-criteria-for-contra- ceptive-use/ukmec/

22. Long-acting reversible contraception: implants and intrauterine devices. Practice Bulletin No. 186. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e251–69. doi: 10.1097/AOG.0000000000002400

23. Pinter B. Continuation and compliance of contraceptive use. Eur J Contracept Reprod Health Care 2002;7:178–83.

24. Krashin J, Tang JH, Mody S, Lopez LM. Hormonal and intrauterine methods for contraception for women aged 25 years and younger. The Cochrane Database of Systematic Reviews 2015, Issue 8. Art. No.: CD009805. doi: 10.1002/14651858.CD009805.pub3

PEER REVIEW HISTORY

Received September 18, 2021. Received in revised form December 8, 2021. Accepted December 16, 2021. Peer reviews and author correspondence are available at http://links.lww.com/AOG/C639.